or Try an Advanced Search...

    Technical Analysis for BEAM - Beam Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 21.38 -1.02% -0.22
    BEAM closed down 1.02 percent on Friday, April 26, 2024, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 8
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BEAM trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -1.02%
    Down 3 Days in a Row Weakness -1.02%
    Gapped Down Weakness -1.02%
    Oversold Stochastic Weakness -1.02%
    Wide Bands Range Expansion -5.98%
    Older End-of-Day Signals for BEAM ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 13 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    Up 1% about 14 hours ago
    Down 2 % about 18 hours ago
    Down 1% about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BEAM Chart by TradingView
    Basic chart:

    Profile

    Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Acute Myeloid Leukemia Gene Therapy Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder

    Is BEAM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
    Apr 11 Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
    Apr 2 Verve drops after pausing trial enrollments for lead asset
    Mar 28 Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
    Mar 26 Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    Mar 1 Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
    Feb 29 News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat
    Feb 28 Beam reverses gains after mixed shelf offering
    Feb 28 Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
    Feb 28 Beam Therapeutics Full Year 2023 Earnings: Beats Expectations
    See more BEAM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 49.5
    52 Week Low 16.95
    Average Volume 1,535,753
    200-Day Moving Average 27.30
    50-Day Moving Average 32.04
    20-Day Moving Average 26.29
    10-Day Moving Average 23.72
    Average True Range 1.56
    RSI (14) 20.63
    ADX 34.82
    +DI 12.18
    -DI 34.57
    Chandelier Exit (Long, 3 ATRs) 29.53
    Chandelier Exit (Short, 3 ATRs) 25.51
    Upper Bollinger Bands 32.36
    Lower Bollinger Band 20.21
    Percent B (%b) 0.1
    BandWidth 46.19
    MACD Line -2.80
    MACD Signal Line -2.47
    MACD Histogram -0.3338
    Fundamentals Value
    Market Cap 1.74 Billion
    Num Shares 81.5 Million
    EPS -4.17
    Price-to-Earnings (P/E) Ratio -5.13
    Price-to-Sales 29.03
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.64
    Resistance 3 (R3) 22.69 22.32 22.43
    Resistance 2 (R2) 22.32 22.00 22.30 22.36
    Resistance 1 (R1) 21.85 21.80 21.67 21.80 22.29
    Pivot Point 21.48 21.48 21.39 21.46 21.48
    Support 1 (S1) 21.01 21.16 20.83 20.96 20.47
    Support 2 (S2) 20.64 20.96 20.62 20.40
    Support 3 (S3) 20.17 20.64 20.33
    Support 4 (S4) 20.12